IBOV 167,921.80 ▼ 0.75% IPC MEX 69,779.20 ▼ 0.01% MERVAL 2,848,945 — — USD/BRL5.44▼ 0.03% USD/MXN18.53▼ 1.37% USD/CLP976.32▼ 1.78% USD/COP3,224▼ 0.14% USD/PEN3.46▼ 0.10% USD/ARS1,544▲ 0.52% USD/UYU40.19▼ 0.01% USD/PYG5,915▼ 0.84% USD/BOB12.00▼ 0.58% USD/DOP60.39▼ 0.05% USD/CRC449.70▼ 0.39% USD/GTQ7.64— 0.00% USD/HNL26.89▲ 0.02% USD/NIO36.62— 0.00% USD/VES887.35▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.69▼ 0.19% USD/TTD6.65▼ 0.91% EUR/BRL6.09▲ 1.24% BRENT 109.58 ▼ 5.38% WTI 100.12 ▼ 1.61% IRON ORE 161.91 — — COPPER 6.65 ▲ 2.24% GOLD 4,073 ▲ 0.85% SILVER 54.49 ▲ 0.70% SOY 1,250 ▲ 0.70% CORN 450.25 ▼ 1.04% WHEAT 614.75 ▼ 0.20% COFFEE 294.35 ▼ 2.19% SUGAR 19.26 ▲ 0.84% ORANGE JUICE 143.20 ▲ 5.45% COTTON 77.90 ▼ 1.47% COCOA 5,581 ▲ 1.66% BEEF 230.73 ▲ 0.33% CATTLE 346.40 ▼ 1.00% LITHIUM 62.43 ▲ 1.89% PETR4 53.31 ▼ 1.06% VALE3 62.88 ▼ 2.33% ITUB4 41.42 ▼ 0.67% BBDC4 15.69 ▼ 1.63% ABEV3 15.40 ▲ 0.20% BBAS3 17.59 ▲ 0.69% B3SA3 15.27 ▲ 1.33% WEGE3 45.78 ▲ 2.81% PRIO3 69.21 ▼ 2.71% SUZB3 47.14 ▼ 0.55% RENT3 31.14 ▼ 1.67% AZZA3 16.72 ▲ 1.15% CSAN3 2.69 ▼ 2.89% RAIZ4 0.34 — 0.00% PCAR3 2.22 ▼ 3.48% GMAT3 3.74 ▲ 2.19% PSSA3 47.75 ▼ 0.89% CVCB3 0.98 — 0.00% POSI3 3.56 ▼ 0.84% SLCE3 16.97 ▼ 2.75% NATU3 5.68 ▼ 3.89% BRKM5 3.80 ▲ 19.50% RANI3 7.34 ▼ 0.54% CSNA3 4.76 ▼ 4.99% IBOV 167,921.80 ▼ 0.75% IPC MEX 69,779.20 ▼ 0.01% MERVAL 2,848,945 — — USD/BRL 5.34 ▼ 1.32% USD/MXN 18.69 ▲ 0.62% USD/CLP 983.47 ▼ 0.57% USD/COP 3,149 ▲ 3.06% USD/PEN 3.45 ▲ 0.17% USD/ARS 1,537 ▼ 0.28% USD/UYU 40.21 ▲ 3.57% USD/PYG 5,803 ▲ 3.78% USD/BOB 11.97 ▲ 4.93% USD/DOP 60.54 ▲ 1.83% USD/CRC 451.24 ▲ 2.13% USD/GTQ 7.64 ▲ 3.23% USD/HNL 26.87 ▲ 3.37% USD/NIO 36.62 ▲ 2.81% USD/VES 885.08 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 2.63% USD/TTD 6.71 ▲ 2.07% EUR/BRL 5.95 ▲ 7.53% BRENT 109.58 ▼ 5.38% WTI 100.12 ▼ 1.61% IRON ORE 161.91 — — COPPER 6.65 ▲ 2.24% GOLD 4,073 ▲ 0.85% SILVER 54.49 ▲ 0.70% SOY 1,250 ▲ 0.70% CORN 450.25 ▼ 1.04% WHEAT 614.75 ▼ 0.20% COFFEE 294.35 ▼ 2.19% SUGAR 19.26 ▲ 0.84% ORANGE JUICE 143.20 ▲ 5.45% COTTON 77.90 ▼ 1.47% COCOA 5,581 ▲ 1.66% BEEF 230.73 ▲ 0.33% CATTLE 346.40 ▼ 1.00% LITHIUM 62.43 ▲ 1.89% PETR4 53.31 ▼ 1.06% VALE3 62.88 ▼ 2.33% ITUB4 41.42 ▼ 0.67% BBDC4 15.69 ▼ 1.63% ABEV3 15.40 ▲ 0.20% BBAS3 17.59 ▲ 0.69% B3SA3 15.27 ▲ 1.33% WEGE3 45.78 ▲ 2.81% PRIO3 69.21 ▼ 2.71% SUZB3 47.14 ▼ 0.55% RENT3 31.14 ▼ 1.67% AZZA3 16.72 ▲ 1.15% CSAN3 2.69 ▼ 2.89% RAIZ4 0.34 — 0.00% PCAR3 2.22 ▼ 3.48% GMAT3 3.74 ▲ 2.19% PSSA3 47.75 ▼ 0.89% CVCB3 0.98 — 0.00% POSI3 3.56 ▼ 0.84% SLCE3 16.97 ▼ 2.75% NATU3 5.68 ▼ 3.89% BRKM5 3.80 ▲ 19.50% RANI3 7.34 ▼ 0.54% CSNA3 4.76 ▼ 4.99%
since 2009
Monday, November 2, 2026

Covid-19 Brazil

Analysis: What Is Delaying Development of Brazilian Nasal Spray Vaccine for Covid-19

By · January 15, 2021 · 2 min read

RIO DE JANEIRO, BRAZIL – The fully Brazilian nasal spray vaccine is still in its pre-clinical trial phase and lagging behind because of the lack of investment in science in Brazil.

World science has not stopped evolving because Brazil has invested little in local scientific research. While other countries have already approved vaccines against the novel coronavirus which are being produced on a large scale, developed by local companies, Brazilian science is crawling.

Brazilian vaccine: researchers have been meeting since April 2020 to find the ideal immunizer (Germano Lüders / Exame)
Brazilian vaccine: researchers have been meeting since April 2020 to find the ideal immunizer .
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

This lag is not for lack of effort. Infectologist Jorge Elias Kalil Filho and his team explain the challenges involved in the development of science in a country investing increasingly less in the area. Since April 2020, he and over 40 multidisciplinary professionals meet almost daily in a laboratory to develop a nasal spray vaccine, aimed at halting a pandemic that has already infected over 92 million patients worldwide.

In addition to the lack of public funds, the Brazilian private sector also invests little in scientific development. According to economist Paulo Feldmann, associate professor at the University of São Paulo School of Economics and Administration and researcher at Fudan University in China, the reason is clear. “Brazilian companies are not large because they have not invested in innovation. Without investment in innovation, one doesn’t grow. And why haven’t they ever invested in innovation? Because there is no fiscal incentive,” he says.

The Brazilian vaccine stumbles into problems that range from bureaucracy to the dollar rate – which raises the cost of components required for the production of an immunizer, imported in its majority. With the shortage, Brazilian science becomes obsolete, uncompetitive and slow in fighting periods of crisis like the novel coronavirus pandemic.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.